Table 3.

Outcomes in CLL patients randomized to the non-lenalidomide group

Patient no.	Current status	Cause of death	Post randomization duration (months)
9	Alive/CR	NA	48+
10	Dead	PD	27
11	Alive/PD	NA	35+
12	Alive/CR	NA	34+
13	Dead/CR	GVHD	9
14	Alive/CR	NA	24+
15	Dead	PD	14
16	Alive/PR	NA	24+
17	Alive/PR	NA	13+

CR indicates complete response; NA, not applicable; PD, progressive disease; PR, partial response.